U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.
- Self-compassion may protect perfectionists from getting depressed
- Young men’s drinking tied to later liver disease risk
- Diarrhea kills 26 Congolese refugees in Uganda, infects hundreds: U.N.
- Blacks in U.S. lose quality of life due to fewer knee replacements
- Japan wins WTO dispute over Fukushima-related food
(Reuters Health) - An approach to nursing home care that fosters interest and social interaction among patients and staff may reduce agitation and other neuropsychiatric symptoms in dementia sufferers and improve their quality of life, a recent trial suggests.
(Reuters Health) - Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.
AMSTERDAM Dutch prosecutors on Thursday rejected a call by civil groups, hospitals and the city of Amsterdam to open a criminal case against major tobacco companies, saying the firms had adequately warned smokers of the health risks.
COPENHAGEN/LONDON The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.